Sphere Fluidics will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies. The projects being undertaken include a licence agreement with Aldevron, a leading US service provider, to bring to market the Lentiviral Plasmids created by Oxford Genetics; and a collaboration project with Sphere Fluidics to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cells. The agreements include a licence from Ryan Cawood to bring Sphere Fluidics 's Oxford therapy to market and a collaborative project with Sphere Fluidics to develop automated Oxford Genetics systems for gene editing in mammalian cells. The remaining agreements are confidential deals secured with large pharmaceutical firms.
Sphere Fluidics will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies. The agreements include a licence from Ryan Cawood to bring Sphere Fluidics 's Oxford therapy to market and a collaborative project with Sphere Fluidics to develop automated Oxford Genetics systems for gene editing in mammalian cells. The remaining agreements are confidential deals secured with large pharmaceutical firms.